Geron Corporation Profile Avatar - Palmy Investing

Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, …

Biotechnology
US, Foster City [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Geron Corporation mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of GERN's Analysis
CIK: 886744 CUSIP: 374163103 ISIN: US3741631036 LEI: - UEI: -
Secondary Listings
GERN has no secondary listings inside our databases.